Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02071537|
Recruitment Status : Recruiting
First Posted : February 26, 2014
Last Update Posted : August 23, 2017
The purpose of this research study is to test the safety of chloroquine in combination with carboplatin and gemcitabine and see what effects (good and bad) it has on advanced solid tumors.
Also, the research study will be increasing the dose of chloroquine to find the highest dose of chloroquine that can be given in combination with carboplatin and gemcitabine without causing severe side effects.
|Condition or disease||Intervention/treatment||Phase|
|Malignant Neoplasm Solid Tumors||Drug: Chloroquine Drug: Carboplatin Drug: Gemcitabine||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1 Study of Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors|
|Study Start Date :||May 2014|
|Estimated Primary Completion Date :||January 2018|
|Estimated Study Completion Date :||December 2018|
Experimental: Chloroquine with Carboplatin/Gemcitabine
Chloroquine administered orally daily to start one week prior to Carboplatin (AUC5)/Gemcitabine (1250mg/m2). Chloroquine dose is escalating.
Dose is 50, 100, 150, and 200 mg per day cohorts. It is given one week prior to the initiation of chemotherapy and then given for four 21 day cycles in combination with chemotherapy.
Administered day 1 of each 21 day cycle for 4-6 cycles.
Administered days 1 and 8 of each 21 day cycle for 4-6 cycles.
Other Name: Gemzar
- Maximum tolerated dose of chloroquine when combined with Carboplatin/Gemcitabine [ Time Frame: Up to 12 months ]
- Time to Disease Progression [ Time Frame: Up to 24 months ]
- Time of Overall Survival [ Time Frame: Up to 24 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02071537
|Contact: UC Cancer Institute Clinical Trials Officeemail@example.com|
|United States, Ohio|
|University of Cincinnati Cancer Institute||Recruiting|
|Cincinnati, Ohio, United States, 45267-0502|
|Principal Investigator: Nagla Karim, MD, PhD|
|Sub-Investigator: Johm Morris, MD|
|Sub-Investigator: Sadia Benzaquin, MD|
|Sub-Investigator: Pankaj Desai, MS, PhD|
|Sub-Investigator: James Driscol, MD|
|Sub-Investigator: Ahmed Khaled, MD|
|Sub-Investigator: Jun Ying, PhD|
|Principal Investigator:||Nagla Abdel-Karim, MD||University of Cincinnati|